{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:50:12Z","timestamp":1789012212421,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007932","name":"Gansu Agricultural University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007932","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.beha.2020.101148","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T02:04:27Z","timestamp":1579226667000},"page":"101148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders"],"prefix":"10.1016","volume":"33","author":[{"given":"Gary A.","family":"Ulaner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2020.101148_bib1","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2020.101148_bib2","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2020.101148_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2020.101148_bib4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2020.101148_bib5","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101148_bib6","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ijrobp.2008.08.037","article-title":"Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma","volume":"74","author":"Kim","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.beha.2020.101148_bib7","first-page":"513","article-title":"18F-FDG PET\/CT in myeloma with presumed solitary plasmocytoma of bone","volume":"22","author":"Nanni","year":"2008","journal-title":"In Vivo"},{"key":"10.1016\/j.beha.2020.101148_bib8","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3324\/haematol.12654","article-title":"FDG-positron-emission tomography for staging and therapeutic assessment in patients with plasmacytoma","volume":"93","author":"Salaun","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2020.101148_bib9","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1158\/1078-0432.CCR-13-2910","article-title":"Impact of initial FDG-PET\/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma","volume":"20","author":"Fouquet","year":"2014","journal-title":"Clin Cancer Res : Off J Am Assoc Canc Res"},{"key":"10.1016\/j.beha.2020.101148_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","article-title":"FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: a systematic review and meta-analysis","volume":"37","author":"Lu","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.beha.2020.101148_bib11","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/cncr.26467","article-title":"(1)(8)F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review","volume":"118","author":"van Lammeren-Venema","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2020.101148_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3324\/haematol.2013.091918","article-title":"The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma","volume":"99","author":"Caers","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2020.101148_bib13","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2020.101148_bib14","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2020.101148_bib15","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101148_bib16","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101148_bib17","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101148_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beha.2020.101148_bib19","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging \"early myeloma\"","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2020.101148_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1477-7819-5-68","article-title":"11C-choline vs. 18F-FDG PET\/CT in assessing bone involvement in patients with multiple myeloma","volume":"5","author":"Nanni","year":"2007","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.beha.2020.101148_bib21","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s00259-016-3392-7","article-title":"18F-fluorocholine versus 18F-fluorodeoxyglucose for PET\/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study","volume":"43","author":"Cassou-Mounat","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.beha.2020.101148_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7150\/thno.13921","article-title":"11C-Methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement","volume":"6","author":"Lapa","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.beha.2020.101148_bib23","first-page":"1592","article-title":"18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment","volume":"47","author":"Agool","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.beha.2020.101148_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12149-014-0931-9","article-title":"Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET\/CT for the detection of active lesions of multiple myeloma","volume":"29","author":"Okasaki","year":"2015","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.beha.2020.101148_bib25","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2967\/jnumed.116.186361","article-title":"Current concepts in (68)Ga-dotatate imaging of neuroendocrine neoplasms: interpretation, biodistribution, dosimetry, and molecular strategies","volume":"58","author":"Bodei","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.beha.2020.101148_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2020.101148_bib27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2020.101148_bib28","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2020.101148_bib29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.euo.2019.01.001","article-title":"Theranostics for advanced prostate cancer: current indications and future developments","volume":"2","author":"Farolfi","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.beha.2020.101148_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","article-title":"A review on CXCR4\/CXCL12 axis in oncology: no place to hide","volume":"49","author":"Domanska","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beha.2020.101148_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/leu.2008.299","article-title":"CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers","volume":"23","author":"Burger","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2020.101148_bib32","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET imaging of CXCR4 receptors in cancer by a new optimized ligand","volume":"6","author":"Demmer","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.beha.2020.101148_bib33","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","article-title":"PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent","volume":"52","author":"Gourni","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.beha.2020.101148_bib34","first-page":"219","article-title":"Chemokine receptor-4 targeted PET\/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET\/CT","volume":"49","author":"Pan","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.beha.2020.101148_bib35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7150\/thno.16576","article-title":"[(68)Ga]Pentixafor-PET\/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [(18)F]FDG and laboratory values","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.beha.2020.101148_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnumed.115.167361","article-title":"First-in-Human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease","volume":"57","author":"Herrmann","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.beha.2020.101148_bib37","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.7150\/thno.19050","article-title":"CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma","volume":"7","author":"Lapa","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.beha.2020.101148_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2020.101148_bib39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1182\/blood-2017-09-807263","article-title":"Copper 64-labeled daratumumab as a PET\/CT imaging tracer for multiple myeloma","volume":"131","author":"Caserta","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2020.101148_bib40","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.117.196063","article-title":"Preclinical development of CD38-targeted [(89)Zr]Zr-DFO-daratumumab for imaging multiple myeloma","volume":"59","author":"Ghai","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.beha.2020.101148_bib41","unstructured":"Ulaner GA, Sobol N, O'Donoghue J, Kirov AS, Riedl C, Min R, et al. CD38-targeted immunoPET of multiple myeloma: from xenograft models to first-in-human imaging. Radiology, in press."},{"key":"10.1016\/j.beha.2020.101148_bib42","doi-asserted-by":"crossref","first-page":"974","DOI":"10.2967\/jnumed.108.060392","article-title":"Development and characterization of clinical-grade 89Zr-trastuzumab for HER2\/neu immunoPET imaging","volume":"50","author":"Dijkers","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.beha.2020.101148_bib43","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2967\/jnumed.117.202010","article-title":"First-in-Human human epidermal growth factor receptor 2-targeted imaging using (89)Zr-pertuzumab PET\/CT: dosimetry and clinical application in patients with breast cancer","volume":"59","author":"Ulaner","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.beha.2020.101148_bib44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beha.2020.101148_bib45","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2020.101148_bib46","doi-asserted-by":"crossref","first-page":"20485","DOI":"10.1039\/C9NR06512A","article-title":"Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma","volume":"11","author":"Detappe","year":"2019","journal-title":"Nanoscale"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692620300098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:11Z","timestamp":1761498311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692620300098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1521692620300098"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2020.101148","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2020.101148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101148"}}